Merck to Acquire Eyebiotech Limited for $3 Billion
Slice of Healthcare Team
05/31/2024
Key Highlights
- Merck acquires Eyebiotech for up to $3 billion
- Eyebiotech’s Restoret™ to advance into pivotal trials in 2024
- Acquisition expands Merck’s ophthalmology pipeline
- Potential milestone payments up to $1.7 billion
Source: Business Wire
Notable Quotes
“ We continue to execute on our science-led business development strategy to expand and diversify our pipeline. ”
— Dr. Dean Y. Li, President, Merck Research Laboratories
“ The EyeBio team has successfully assembled a pipeline of novel candidates with the potential to provide new treatment options for patients with retinal disease. ”
Dr. David R. Guyer, CEO and President at Eyebiotech
“ Less than three years ago, EyeBio was hatched to translate Dr. David Guyer’s idea for a potential new therapy for retinal diseases into a reality. ”
Kate Bingham, Board Chair at EyeBio
SoHC's Take
This acquisition marks a significant step for Merck in broadening its reach within the ophthalmology sector. By integrating Eyebiotech’s innovative pipeline, particularly the promising Restoret™, Merck positions itself at the forefront of addressing retinal diseases like diabetic macular edema and neovascular age-related macular degeneration. This strategic move underscores Merck’s commitment to advancing its pipeline through targeted acquisitions, reinforcing its dedication to delivering cutting-edge treatments to patients worldwide.
